NEW YORK (TheStreet) -- Barclays decreased its price target on CME Group (CME) to $75, trimmed its estimates and set an "equal weight" rating. The firm made the moves to reflect the company's second-quarter earnings and revenue miss.
The stock closed at $73.94 on Thursday.
TheStreet Ratings team rates CME GROUP INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate CME GROUP INC (CME) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow."
You can view the full analysis from the report here: CME Ratings ReportCME data by YCharts